Tiago Mestre1, Joaquim Ferreira. 1. Faculdade de Medicina de Lisboa, Centro de Estudos Egas Moniz, Avenida Egas Moniz, 1649 - 028 Lisboa, Portugal.
Abstract
BACKGROUND: Epilepsy is a neurological condition with an increased probability of seizure occurrence through time. Although many anti-epileptic drugs (AEDs) exist, they fail to treat seizures in 30% of patients with epilepsy. For these patients, new AEDs potentially more efficacious and safe are developed. OBJECTIVE: To evaluate the effectiveness of eslicarbazepine acetate (ESL) in the treatment of patients with refractory epilepsy. METHODS: A review of the literature was carried out using PubMed central. A direct contact with the drug manufacturer and developer was made. RESULTS/ CONCLUSION: ESL is an AED that acts by inhibiting voltage-gated sodium channels. It has proved efficacious in the treatment of patients with refractory focal-onset epilepsy with a good safety profile. Evaluation of its use for treating other epileptic syndromes and its role as an initial treatment option for patients with epilepsy is warranted.
BACKGROUND:Epilepsy is a neurological condition with an increased probability of seizure occurrence through time. Although many anti-epileptic drugs (AEDs) exist, they fail to treat seizures in 30% of patients with epilepsy. For these patients, new AEDs potentially more efficacious and safe are developed. OBJECTIVE: To evaluate the effectiveness of eslicarbazepine acetate (ESL) in the treatment of patients with refractory epilepsy. METHODS: A review of the literature was carried out using PubMed central. A direct contact with the drug manufacturer and developer was made. RESULTS/ CONCLUSION:ESL is an AED that acts by inhibiting voltage-gated sodium channels. It has proved efficacious in the treatment of patients with refractory focal-onset epilepsy with a good safety profile. Evaluation of its use for treating other epileptic syndromes and its role as an initial treatment option for patients with epilepsy is warranted.
Authors: S D Shorvon; E Trinka; B J Steinhoff; M Holtkamp; V Villanueva; J Peltola; E Ben-Menachem Journal: J Neurol Date: 2017-01-18 Impact factor: 4.849
Authors: Catalina Gómez; Pablo Arbeláez; Miguel Navarrete; Catalina Alvarado-Rojas; Michel Le Van Quyen; Mario Valderrama Journal: Sci Rep Date: 2020-12-11 Impact factor: 4.379